Horizon Technology downgraded to Sell from Neutral at Compass Point

Compass Point downgraded Horizon Technology (HRZN) to Sell from Neutral with a $10 price target after Evelo Biosciences (EVLO) announced its Phase 2 clinical study with EDP2939 in moderate psoriasis did not achieve the study’s primary endpoint.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on HRZN:

Disclaimer & DisclosureReport an Issue